WO2022052964A1 - 用于重编程的功能性片段、组合及其应用 - Google Patents

用于重编程的功能性片段、组合及其应用 Download PDF

Info

Publication number
WO2022052964A1
WO2022052964A1 PCT/CN2021/117302 CN2021117302W WO2022052964A1 WO 2022052964 A1 WO2022052964 A1 WO 2022052964A1 CN 2021117302 W CN2021117302 W CN 2021117302W WO 2022052964 A1 WO2022052964 A1 WO 2022052964A1
Authority
WO
WIPO (PCT)
Prior art keywords
expression
transcription factors
promote
functional
functional fragments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2021/117302
Other languages
English (en)
French (fr)
Chinese (zh)
Inventor
刘月光
陈如雷
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neuragen Biotherapeutics Suzhou Co Ltd
Original Assignee
Neuragen Biotherapeutics Suzhou Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuragen Biotherapeutics Suzhou Co Ltd filed Critical Neuragen Biotherapeutics Suzhou Co Ltd
Priority to CN202180054720.4A priority Critical patent/CN116437943A/zh
Priority to EP21866017.3A priority patent/EP4212624A4/en
Priority to US18/024,504 priority patent/US20240026379A1/en
Priority to JP2023515253A priority patent/JP7680072B2/ja
Priority to KR1020237011913A priority patent/KR20230082024A/ko
Publication of WO2022052964A1 publication Critical patent/WO2022052964A1/zh
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0619—Neurons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0622—Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/13—Nerve growth factor [NGF]; Brain-derived neurotrophic factor [BDNF]; Cilliary neurotrophic factor [CNTF]; Glial-derived neurotrophic factor [GDNF]; Neurotrophins [NT]; Neuregulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/08—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from cells of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/30—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from cancer cells, e.g. reversion of tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Definitions

  • the present invention belongs to the fields of biotechnology and gene therapy, in particular, the present invention relates to a method for transdifferentiation of glial cell-derived cells into neurons, and a method for applying this method to repair damage to the nervous system or to treat glial cell-derived tumors .
  • the main pathological changes caused by mammalian central nervous system injury and various neurodegenerative diseases are irreversible neuronal degeneration and necrosis and neural circuit damage. How to replace dead and lost neurons in the damaged and diseased brain or spinal cord and rebuild neural circuits is a key step in treatment. Because the central nervous system (brain and spinal cord) of adult mammals has a very limited ability to repair itself, it is difficult to make up for the loss of neuronal cells on its own.
  • Glioma is abbreviated as glioma, also known as gliocytoma. In a broad sense, it refers to all tumors of neuroepithelial origin, and in a narrow sense, it refers to tumors derived from various types of glial cells. Glioma is one of the most lethal malignant tumors and the most common primary central nervous system tumor, accounting for 30% of brain and central nervous system tumors, and 80% of brain malignant brain tumors. threat.
  • glioblastoma At present, the treatment of glioblastoma is still in the medical field to meet the clinical needs.
  • some studies have found that some neurogenic transcription factors or combinations of transcription factors can transform glioma cells into neurons in vitro or in vivo, and limit the proliferation ability of glioma cells.
  • the existing transcription factors or combinations of transcription factors have only been proven to be used for in vitro or in vivo transformation with low efficiency, making it difficult to achieve practical clinical applications.
  • the present invention provides a set of transcription factors, combinations of transcription factors that synergistically promote the transdifferentiation of glial cells, reprogramming into functional neurons or neuron-like cells, by increasing the expression of this set of transcription factors in vivo or in vitro, and The application of this group of transcription factors in the preparation of drugs for nervous system diseases.
  • a set of functional fragments that can synergistically promote the transdifferentiation of glial cells wherein the functional fragments contain at least one functional fragment that promotes the expression of transcription factors, selected from the group consisting of NeuroD1, Brn2 , Ascl1, Ngn2, Gsx1, Tbr1, Dlx2, Ptf1a, Pax6 and/or Otx2 and other transcription factor expression functional fragments.
  • the "transdifferentiation” refers to transdifferentiation or reprogramming of glial cells into functional neuronal cells.
  • the functional fragments that promote the expression of transcription factors at least include functional fragments that promote the expression of Ascl1 transcription factors.
  • the Ascl1 is enhanced Ascl1, and its amino acid sequence is shown in SEQ ID No: 41.
  • the functional fragment that promotes the expression of transcription factor at least includes a functional fragment that promotes the expression of NeuroD1 transcription factor.
  • the functional fragments that promote the expression of transcription factors at least include functional fragments that promote the expression of Brn2 transcription factors.
  • the functional fragments that promote the expression of transcription factors at least include functional fragments that promote the expression of Ngn2 transcription factors.
  • the functional fragments that promote the expression of transcription factors at least include functional fragments that promote the expression of Gsx1 transcription factors.
  • the functional fragments that promote the expression of transcription factors include at least a functional fragment that promotes the expression of Tbr1 transcription factors.
  • the functional fragments that promote the expression of transcription factors at least include functional fragments that promote the expression of Dlx2 transcription factors.
  • the functional fragments that promote the expression of transcription factors at least include functional fragments that promote the expression of Ptf1a transcription factors.
  • the functional fragments that promote the expression of transcription factors at least include functional fragments that promote the expression of Pax6 transcription factors.
  • the functional fragments that promote the expression of transcription factors at least include functional fragments that promote the expression of Otx2 transcription factors.
  • the functional fragment combination contains at least two functional fragments that promote the expression of transcription factors, selected from the group consisting of NeuroD1, Brn2, Ascl1, Ngn2, Gsx1, Tbr1, Dlx2, Ptf1a, Pax6 and/or Functional fragments expressed by transcription factors such as Otx2.
  • the functional fragments that promote the expression of transcription factors include at least a functional fragment that promotes the expression of Brn2 transcription factors and another functional fragment that promotes the expression of transcription factors, and the other functional fragments that promote the expression of transcription factors
  • the functional fragment is selected from any functional fragment that promotes the expression of transcription factors such as NeuroD1, Ascl1, Ngn2, Gsx1, Tbr1, Dlx2, Ptf1a, Pax6 or Otx2; more preferably, said another function that promotes the expression of transcription factors
  • the sexual fragment is selected from any functional fragment that promotes the expression of transcription factors such as NeuroD1, Ascl1 or Ngn2.
  • the functional fragments that promote the expression of transcription factors include at least a functional fragment that promotes the expression of NeuroD1 transcription factors and another functional fragment that promotes the expression of transcription factors, and the other functional fragments that promote the expression of transcription factors
  • the functional fragment is selected from any functional fragment that promotes the expression of transcription factors such as Brn2, Ascl1, Ngn2, Gsx1, Tbr1, Dlx2, Ptf1a, Pax6 or Otx2; more preferably, said another function that promotes the expression of transcription factors
  • the sexual fragment is selected from any functional fragment that promotes the expression of transcription factors such as Brn2, Ascl1 or Ngn2.
  • the functional fragments that promote the expression of transcription factors include at least a functional fragment that promotes the expression of Gsx1 transcription factors and another functional fragment that promotes the expression of transcription factors, and the other functional fragments that promote the expression of transcription factors
  • the functional fragment is selected from any functional fragment that promotes the expression of transcription factors such as NeuroD1, Ascl1, Ngn2, Brn2, Tbr1, Dlx2, Ptf1a, Pax6 or Otx2; more preferably, said another function that promotes the expression of transcription factors
  • the sexual fragment is selected from any functional fragment that promotes the expression of transcription factors such as Ascl1, Ngn2 or Tbr1.
  • the functional fragment that promotes the expression of transcription factors at least includes a functional fragment that promotes the expression of Tbr1 transcription factor and another functional fragment that promotes the expression of transcription factors, and the other functional fragment that promotes the expression of transcription factors
  • the functional fragment is selected from any functional fragment that promotes the expression of transcription factors such as NeuroD1, Ascl1, Ngn2, Brn2, Gsx1, Dlx2, Ptf1a, Pax6 or Otx2; more preferably, said another function that promotes the expression of transcription factors
  • the sexual fragment is selected from any functional fragment that promotes the expression of transcription factors such as Ascl1, Ngn2 or Gsx1.
  • the functional fragments that promote the expression of transcription factors include at least a functional fragment that promotes the expression of Dlx2 transcription factors and another functional fragment that promotes the expression of transcription factors, and the other functional fragments that promote the expression of transcription factors
  • the functional fragment is selected from any functional fragment that promotes the expression of transcription factors such as NeuroD1, Ascl1, Ngn2, Brn2, Tbr1, Gsx1, Ptf1a, Pax6 or Otx2; more preferably, said another function that promotes the expression of transcription factors
  • the sexual fragment is selected from any functional fragment that promotes the expression of transcription factors such as Ascl1, Ngn2 or Ptf1a.
  • the functional fragments that promote the expression of transcription factors include at least a functional fragment that promotes the expression of Ptf1a transcription factors and another functional fragment that promotes the expression of transcription factors, and the other functional fragments that promote the expression of transcription factors
  • the functional fragment is selected from any functional fragment that promotes the expression of transcription factors such as NeuroD1, Ascl1, Ngn2, Brn2, Tbr1, Gsx1, Dlx2, Pax6 or Otx2; more preferably, said another function that promotes the expression of transcription factors
  • the sexual fragment is selected from any functional fragment that promotes the expression of transcription factors such as Ascl1, Ngn2 or Dlx2.
  • the functional fragment that promotes the expression of transcription factors includes at least a functional fragment that promotes the expression of Pax6 transcription factor and another functional fragment that promotes the expression of transcription factors, and the other functional fragment that promotes the expression of transcription factors
  • the functional fragment is selected from any functional fragment that promotes the expression of transcription factors such as NeuroD1, Ascl1, Ngn2, Brn2, Tbr1, Gsx1, Ptf1a, Dlx2 or Otx2; more preferably, said another function that promotes the expression of transcription factors
  • the sexual fragment is selected from any functional fragment that promotes the expression of transcription factors such as Ascl1, Ngn2 or Otx2.
  • the functional fragments that promote the expression of transcription factors include at least a functional fragment that promotes the expression of Otx2 transcription factors and another functional fragment that promotes the expression of transcription factors, and the other functional fragments that promote the expression of transcription factors
  • the functional fragment is selected from any functional fragment that promotes the expression of transcription factors such as NeuroD1, Ascl1, Ngn2, Brn2, Tbr1, Gsx1, Ptf1a, Dlx2 or Pax6; more preferably, said another function that promotes the expression of transcription factors
  • the sexual fragment is selected from any functional fragment that promotes the expression of transcription factors such as Ascl1, Ngn2 or Pax6.
  • the functional fragment that promotes the expression of transcription factors at least includes a functional fragment that promotes the expression of any one of Ascl1 or Ngn2 and another functional fragment that promotes the expression of transcription factors, and the other A functional fragment that promotes the expression of transcription factors is selected from any functional fragment that promotes the expression of transcription factors such as NeuroD1, Brn2, Gsx1, Tbr1, Dlx2, Ptf1a, Pax6 or Otx2.
  • the functional fragments that can synergistically promote the transdifferentiation of glial cells include at least a functional fragment that promotes the expression of two transcription factors NeuroD1 and Brn2, or a functional fragment that promotes the expression of two transcription factors Gsx1 and Tbr1 Fragments, or functional fragments that promote the expression of two transcription factors, Dlx2 and Ptf1a, or functional fragments that promote the expression of two transcription factors, Pax6 and Otx2.
  • the functional fragment that can synergistically promote the transdifferentiation of glial cells includes at least a functional fragment that promotes the expression of transcription factors of either Ascl1 or Ngn2 and another functional fragment that can synergistically promote the transdifferentiation of glial cells.
  • a combination of functional fragments, the other combination of functional fragments that can synergistically promote the transdifferentiation of glial cells is selected from the combination of functional fragments that promote the expression of two transcription factors NeuroD1 and Brn2, or two transcription factors that promote Gsx1 and Tbr1
  • the functional fragment that can synergistically promote the transdifferentiation of glial cells or the functional fragment that promotes the expression of a transcription factor can be a polynucleotide encoding the transcription factor, or a functional protein, polypeptide after polynucleotide translation, or Promote the expression of transcription factors of small molecule drugs, macromolecular drugs, nucleic acid drugs, or polynucleotides or functional proteins, polypeptides, small molecule drugs or macromolecular drugs, nucleic acid drugs that are located upstream of the transcription factors to regulate the expression of transcription factors.
  • the functional fragments that can synergistically promote the transdifferentiation of glial cells or the functional fragments that promote the expression of transcription factors are functional NeuroD1, Brn2, Ascl1, Ngn2, Gsx1, Tbr1, Dlx2, Ptf1a, Proteins of transcription factors such as Pax6 and/or Otx2 or nucleic acid sequences encoding functional proteins of transcription factors such as NeuroD1, Brn2, Ascl1, Ngn2, Gsx1, Tbr1, Dlx2, Ptf1a, Pax6 and/or Otx2; preferably, said synergistic
  • the functional fragments that promote the transdifferentiation of glial cells or the functional fragments that promote the expression of transcription factors are derived from mammals, preferably, from human or non-human primate mammals.
  • the combination of functional fragments is selected from the following group:
  • the combination of functional fragments is selected from the following group: NeuroD1+Brn2; Gsx1+Tbr1; Dlx2+Ptf1a; Pax6+Otx2; or a combination thereof.
  • the functional fragment that can synergistically promote the transdifferentiation of glial cells or the functional fragment that promotes the expression of transcription factors is a functional NeuroD1 protein
  • the protein sequence is such as SEQ ID NO.: 1 or SEQ ID NO.: 1 or SEQ ID NO.: 1 or SEQ ID NO. ID NO.: 2; the polynucleotide sequence encoding the NeuroD1 functional protein is shown in SEQ ID NO.: 3 or SEQ ID NO.: 4.
  • the functional fragment that can synergistically promote the transdifferentiation of glial cells or the functional fragment that promotes the expression of transcription factors is a functional Brn2 protein
  • the protein sequence is such as SEQ ID NO.: 5 or SEQ ID NO.: 5 or SEQ ID NO.: 5 or SEQ ID NO. ID NO.: 6; the polynucleotide sequence encoding the Brn2 functional protein is shown in SEQ ID NO.: 7 or SEQ ID NO.: 8.
  • the functional fragment that can synergistically promote the transdifferentiation of glial cells or the functional fragment that promotes the expression of transcription factors is a functional Ascl1 protein
  • the protein sequence is such as SEQ ID NO.: 9 or SEQ ID NO.: 9 or SEQ ID NO.: 9 or SEQ ID NO. ID NO.: 10 or SEQ ID NO: 41; the polynucleotide sequence encoding the Ascl1 functional protein is shown in SEQ ID NO.: 11 or SEQ ID NO.: 12.
  • the functional fragment that can synergistically promote the transdifferentiation of glial cells or the functional fragment that promotes the expression of transcription factors is a functional Ngn2 protein
  • the protein sequence is such as SEQ ID NO.: 13 or SEQ ID NO.: 13 or SEQ ID NO.: 13 or SEQ ID NO. ID NO.: 14; the polynucleotide sequence encoding the Ngn2 functional protein is shown in SEQ ID NO.: 15 or SEQ ID NO.: 16.
  • the functional fragment that can synergistically promote the transdifferentiation of glial cells or the functional fragment that promotes the expression of transcription factors is a functional Gsx1 protein
  • the protein sequence is such as SEQ ID NO.: 17 or SEQ ID NO.: 17 or SEQ ID NO.: 17 or SEQ ID NO.: 17 ID NO.: 18; the polynucleotide sequence encoding the Gsx1 functional protein is shown in SEQ ID NO.: 19 or SEQ ID NO.: 20.
  • the functional fragment that can synergistically promote the transdifferentiation of glial cells or the functional fragment that promotes the expression of transcription factors is a functional Tbr1 protein
  • the protein sequence is such as SEQ ID NO.: 21 or SEQ ID NO.: 21 or SEQ ID NO.: 21 or SEQ ID NO.: 21 ID NO.: 22; the polynucleotide sequence encoding the Tbr1 functional protein is shown in SEQ ID NO.: 23 or SEQ ID NO.: 24.
  • the functional fragment that can synergistically promote the transdifferentiation of glial cells or the functional fragment that promotes the expression of transcription factors is a functional Dlx2 protein
  • the protein sequence is such as SEQ ID NO.: 25 or SEQ ID NO.: 25 or SEQ ID NO.: 25 or SEQ ID NO. ID NO.: 26; the polynucleotide sequence encoding the Dlx2 functional protein is shown in SEQ ID NO.: 27 or SEQ ID NO.: 28.
  • the functional fragment that can synergistically promote the transdifferentiation of glial cells or the functional fragment that promotes the expression of transcription factors is a functional Ptf1a protein
  • the protein sequence is such as SEQ ID NO.: 29 or SEQ ID NO.: 29 or SEQ ID NO.: 29 or SEQ ID NO.: 29 ID NO.: 30
  • the polynucleotide sequence encoding the functional protein of Ptf1a is shown in SEQ ID NO.: 31 or SEQ ID NO.: 32.
  • the functional fragment that can synergistically promote the transdifferentiation of glial cells or the functional fragment that promotes the expression of transcription factors is a functional Pax6 protein
  • the protein sequence is such as SEQ ID NO.: 33 or SEQ ID NO.: 33 or SEQ ID NO.: 33 or SEQ ID NO. ID NO.: 34; the polynucleotide sequence encoding the functional protein of Pax6 is shown in SEQ ID NO.: 35 or SEQ ID NO.: 36.
  • the functional fragment that can synergistically promote the transdifferentiation of glial cells or the functional fragment that promotes the expression of transcription factors is a functional Otx2 protein
  • the protein sequence is such as SEQ ID NO.: 37 or SEQ ID NO.: 37 or SEQ ID NO.: 37 or SEQ ID NO. ID NO.: 38; the polynucleotide sequence encoding the Otx2 functional protein is shown in SEQ ID NO.: 39 or SEQ ID NO.: 40.
  • the functional fragment that can synergistically promote the transdifferentiation of glial cells or the functional fragment that promotes the expression of transcription factors is an engineered Ascl1 functional protein, and the protein sequence is as shown in SEQ ID NO. :41.
  • the functional protein sequence is the same as SEQ ID NO. : 1, 2, 5, 6, 9, 10, 13, 14, 17, 18, 21, 22, 25, 26, 29, 30, 33, 34, 37, 38, and/or 41 with no sequence homology less than 85%; more preferably, the functional protein sequence is the same as SEQ ID NO.: 1, 2, 5, 6, 9, 10, 13, 14, 17, 18, 21, 22, 25, 26, 29, 30, 33, 34, 37, 38 and/or 41 sequence homology is not less than 95%; optimally, described functional protein sequence and SEQ ID NO.: 1, 2, 5, 6, The sequence homology of 9, 10, 13, 14, 17, 18, 21, 22, 25, 26, 29, 30, 33, 34, 37, 38 and/or 41 is not less than 99%.
  • the functional fragment that can synergistically promote the transdifferentiation of glial cells or the functional fragment that promotes the expression of transcription factors is a polynucleotide encoding a functional protein
  • the functional protein encoding The polynucleic acid sequence with SEQ ID NO.: 3, 4, 7, 8, 11, 12, 15, 16, 19, 20, 23, 24, 27, 28, 31, 32, 35, 36, 39 and/or
  • the sequence homology of 40 is not less than 75%; more preferably, the polynucleic acid sequence encoding functional protein is the same as SEQ ID NO.: 3, 4, 7, 8, 11, 12, 15, 16, 19 , 20, 23, 24, 27, 28, 31, 32, 35, 36, 39 and/or 40 have a sequence homology of not less than 85%; optimally, the polynucleic acid sequence encoding a functional protein Identical to the sequence of SEQ ID NO.: 3, 4, 7, 8, 11, 12, 15, 16, 19, 20, 23, 24, 27, 28, 31, 32, 35, 36, 39 and/or 40 The origin is not less than 95%.
  • the glial cells are any human or non-human mammalian astrocytes, NG2 glial cells, oligodendrocytes, microglia, or damaged glial cells , tumor cells derived from glial cells, etc.; the glial cells in the damaged state are neuronal death and apoptosis caused by mechanical trauma, stroke or neurodegenerative diseases caused by tissue or the surrounding environment of glial cells.
  • Glial cells in a state where nerve signal transduction is blocked or disordered are generally glioma cells, selected from astrocytoma, oligodendroglioma derived from human or non-human mammals , ependymoma, mixed glioma, choroid plexus, neuroepithelial tumor of uncertain origin, neuronal and neuroglial mixed tumor, pineal parenchyma tumor, embryonal tumor, neuroblastoma tumor.
  • the functional nerve cells or nerve-like cells include at least one of the following characteristics:
  • the up-regulated genes include: one or more of DCX, Tuj1, Map2, NeuN, and Synapsin I;
  • the down-regulated genes include: one or more of GFAP, S100 ⁇ , Glast, and Acsbg1;
  • the specific electrophysiological characteristics of nerve cells that is, the cells have resting potentials and action potentials induced by the action of excitatory neurotransmitters or inhibitory neurotransmitters; the generated cell resting potentials are not higher than -50mV, preferably, the resulting cell resting potential is not higher than -55mV, or not higher than -60mV, or not higher than -65mV; the excitatory neurotransmitters include but are not limited to glutamate (glutamate) or kainate, which can induce inward current; the inhibitory neurotransmitters, including but not limited to glycine or gamma aminobutyric acid (GABA), can induce outward current;
  • GABA gamma aminobutyric acid
  • a method for promoting the transdifferentiation of glial cells and reprogramming them into functional neurons or neuron-like cells in the second aspect of the present invention, there is provided a method for promoting the transdifferentiation of glial cells and reprogramming them into functional neurons or neuron-like cells.
  • the method is non-therapeutic and non-diagnostic.
  • the method is an in vitro method.
  • the method is therapeutic.
  • the method includes the step of: contacting the glial cells with the functional fragments that can synergistically promote the transdifferentiation of glial cells according to the first aspect of the present invention or introducing them by means of a delivery system, so that the glial cells are Cells are transdifferentiated and reprogrammed into functional neurons or neuron-like.
  • the glial cells are any human or non-human mammalian astrocytes, NG2 glial cells, oligodendrocytes, microglia, or damaged glial cells , tumor cells derived from glial cells, etc.; the glial cells in the damaged state are neuronal death and apoptosis caused by mechanical trauma, stroke or neurodegenerative diseases caused by tissue or the surrounding environment of glial cells.
  • Glial cells in a state where nerve signal transduction is blocked or disordered are generally glioma cells, selected from astrocytoma, oligodendroglioma derived from human or non-human mammals , ependymoma, mixed glioma, choroid plexus, neuroepithelial tumor of uncertain origin, neuronal and neuroglial mixed tumor, pineal parenchyma tumor, embryonal tumor, neuroblastoma tumor.
  • Any method for increasing the expression of transcription factors that can promote the transdifferentiation of glial cells including but not limited to inducing factors or functional fragments that promote the expression of transcription factors by directly contacting or introducing the glial cells to promote glial cells.
  • the expression of any of NeuroD1, Brn2, Ascl1, Ngn2, Gsx1, Tbr1, Dlx2, Ptf1a, Pax6, Otx2 transcription factors was increased in the cells and promoted the glial cells to exhibit functional neuronal or neuronal characteristics.
  • the inducing factor or the functional fragment that promotes the expression of the transcription factor can be a polynucleotide encoding the transcription factor, or a functional protein or polypeptide after the translation of the polynucleotide, or a functional fragment that promotes NeuroD1, Brn2, Ascl1, Ngn2, Gsx1 , Tbr1, Dlx2, Ptf1a, Pax6, Otx2 transcription factors express small molecule drugs, macromolecular drugs, nucleic acid drugs, or any of the NeuroD1, Brn2, Ascl1, Ngn2, Gsx1, Tbr1, Dlx2, Ptf1a, Pax6, Otx2
  • a polynucleotide or functional protein, polypeptide, small molecule drug or macromolecule drug, nucleic acid drug, etc. whose expression is up-regulated by a transcription factor upstream of the transcription factor is passively absorbed by glial cells or reaches the interior of glial cells through a delivery system to take effect.
  • the delivery system includes, but is not limited to, an expression vector carrying the inducing factor or a functional fragment that promotes the expression of a transcription factor, nanoparticles coated with the inducing factor or a functional fragment that promotes the expression of a transcription factor, and Exosomes containing the inducible factors or functional fragments that promote the expression of transcription factors, cellular vectors (such as modified red blood cells or bacteria, etc.) or viral vectors that are encapsulated with the inducible factors or functional fragments that promote the expression of transcription factors.
  • the targeting effector (such as glial cell-specific antibody, polypeptide or other targeting substances, etc.) of the inducing factor or the functional fragment that promotes the expression of the transcription factor.
  • the inducing factor or the functional fragment that promotes the expression of the transcription factor is a polynucleotide encoding a transcription factor, and the polynucleotide is selected from NeuroD1, Brn2, Ascl1, Ngn2, Gsx1, Tbr1, Transcription factor functional polynucleotides of Dlx2, Ptf1a, Pax6 and/or Otx2; the polynucleotides need to be loaded in a viral or non-viral delivery system.
  • the delivery system includes, but is not limited to, plasmids, viruses, and cell vectors; preferably viral vectors, including but not limited to adenovirus vectors, adeno-associated virus vectors (AAV), retrovirus expression vectors or Lentiviral vectors, etc.
  • viral vectors including but not limited to adenovirus vectors, adeno-associated virus vectors (AAV), retrovirus expression vectors or Lentiviral vectors, etc.
  • the expression vector carrying the transcription factor polynucleotide also carries a glial cell-specific promoter, and the promoter includes but is not limited to the GFAP promoter and the NG2 promoter. , Aldh1L1 promoter, IBA1 promoter, CNP promoter, LCN2 promoter or a genetically engineered promoter variant.
  • the promoter is a GFAP promoter, or a genetically engineered GFAP promoter. More preferably, the human hGFAP promoter (SEQ ID No:42) can be modified into a 683bp truncated version (SEQ ID No:43).
  • the expression vector carrying transcription factor polynucleotides also carries one or more regulatory elements for regulating gene expression, for enhancing the expression level of genes, including but not limited to CMV Enhancers, SV40 enhancers, EN1 enhancers, VP16 fusion proteins or genetically engineered enhancer variants, as well as SV40 polyA tailing signal, human insulin gene polyA tailing signal or WPRE (woodchuck hepatitis B virus post-transcriptional regulation) elements), human MAR sequences or genetically engineered variants.
  • the regulatory element for enhancing expression is the activation domain (SEQ ID NO: 44) of the VP16 protein from Herpes simplex virus, wherein the coding sequence of VP16 (SEQ ID NO: 44) NO:45) can be loaded singly or in clusters, and express a fusion protein of DNA binding region of VP16-transcription factor through a glial cell-specific promoter.
  • the regulatory element for enhancing expression comes from the enhancer (SEQ ID NO: 46) of simian vacuolating virus 40 (Simian vacuolating virus40) SV40, which is inserted before the glial cell-specific promoter, It can enhance the activity of the promoter and improve the efficiency of neuron induction.
  • the expression vector carrying the transcription factor polynucleotide may also carry other functional fragments, and the other functional fragments may be reporter genes or other reprogramming functions.
  • Functional fragments of transcription factors including but not limited to selected from NeuroD1, Brn2, Ascl1, Ngn2, Gsx1, Tbr1, Dlx2, Ptf1a, Pax6, Otx2, etc.; preferably, polynucleotides that can carry at least 2 transcription factors in the same vector
  • the polynucleotides of the two transcription factors can be expressed under one glial cell-specific promoter, or under two glial cell-specific promoters, respectively.
  • IRES or 2A polypeptide (IRES or 2A polypeptide) P2A) elements are equally spaced to enable expression of multiple transcription factors (Pharmaceutics 2019, 11(11), 580; IRES sequences used in the present invention are copied from Addgene#69550; P2A sequences are copied from Addgene#130692).
  • the combination of the two transcription factors is selected from the combination of the transcription factors of NeuroD1 and Brn2, the combination of transcription factors of Gsx1 and Tbr1, the combination of transcription factors of Dlx2 and Ptf1a, the combination of transcription factors of Pax6 and Otx2, the combination of transcription factors of Ascl1 and Ngn2
  • the combination of transcription factors, the molar concentration ratio of the expression amounts of the two transcription factors is 4:1 to 1:4; preferably, the molar concentration ratio of the expression amounts of the two transcription factors is 2:1 to 1:2; optimally , the optimal molar concentration ratio of the expression levels of the two transcription factors is 1:1.
  • the molar concentration ratio of the expression amount of Ascl1 or Ngn2 should not be lower than 20%, preferably, The molar ratio of Ascl1 or Ngn2 expression should not be lower than 33%; optimally, the molar ratio of Ascl1 or Ngn2 should not be lower than 50%; and include a combination of any of the following transcription factors:
  • a combination of Ascl1 and any other transcription factor, and the other transcription factor is selected from NeuroD1, Brn2, Ascl1, Ngn2, Gsx1, Tbr1, Dlx2, Ptf1a, Pax6 or Otx2;
  • Ngn2 a combination of Ngn2 and any other transcription factor, the other transcription factor being selected from NeuroD1, Brn2, Ascl1, Ngn2, Gsx1, Tbr1, Dlx2, Ptf1a, Pax6 or Otx2; and
  • the transcription factors at least include the combination of Ascl1+NeuroD1+Brn2, the combination of Ascl1+Gsx1+Tbr1, the combination of Ascl1+Dlx2+Ptf1a, the combination of Ascl1+Pax6
  • the molar concentration ratio of the expression amounts of the two transcription factors is 4:1 to 1:4; preferably, the molar concentration ratio of the expression amounts of the two transcription factors is 2:1 to 1:2; The optimal molar concentration ratio is 1:1.
  • one or more expression vectors carrying different transcription factor polynucleotides can also be used at the same time, and the transcription factors are selected from NeuroD1, Brn2, Ascl1, Ngn2, Gsx1, Tbr1, Dlx2, Ptf1a, Transcription factor functional polynucleotides of Pax6 and/or Otx2; the preferred combination of vectors is selected from the combination of vectors loaded with the transcription factor NeuroD1 and the transcription factor Brn2, respectively, and the vectors loaded with the transcription factor Gsx1 and the transcription factor Tbr1
  • one or more expression vectors loaded with different transcription factor polynucleotides can also be used at the same time, including at least a combination of expression vectors loaded with Ascl1 or Ngn2 polynucleotides and vectors of other transcription factors,
  • the molar concentration ratio of the expression amount of Ascl1 or Ngn2 should not be lower than 20%, preferably, the molar concentration ratio of the expression amount of Ascl1 or Ngn2 should not be lower than 33%; optimally, the molar concentration ratio of the expression amount of Ascl1 or Ngn2
  • the concentration ratio should not be less than 50%; and is selected from the combination of any of the following carriers:
  • the transcription factor Ngn2 is loaded in combination with a vector loaded with another transcription factor selected from NeuroD1, Brn2, Ascl1, Ngn2, Gsx1, Tbr1, Dlx2, Ptf1a, Pax6 or Otx2; and
  • the expression vector carrying the functional fragment of the transcription factor polynucleotide is a lentiviral vector; the lentiviral vector is loaded with viral ITR sequences, CAG promoters, and functional transcription factor polynucleotides.
  • the coding frame of the fragment and the post-transcriptional regulatory element WPRE, etc.; the expression vector can also carry a reporter gene, but the reporter gene is not necessary in practical applications.
  • WPRE viral ITR sequence+CAG promoter+coding frame of transcription factor polynucleotide and green fluorescent protein GFP+post-transcriptional regulatory element
  • WPRE viral ITR sequence+promoter and coding frame of ampicillin resistance gene, wherein green fluorescence
  • the coding frame of the protein GFP and the promoter and coding frame of the ampicillin resistance gene are not necessary.
  • the polynucleotide of the transcription factor is selected from functional polynucleotides encoding NeuroD1, Brn2, Ascl1, Ngn2, Gsx1, Tbr1, Dlx2, Ptf1a, Pax6 and/or Otx2, specifically, selected from SEQ ID NO.: Sequence of 3, 4, 7, 8, 11, 12, 15, 16, 19, 20, 23, 24, 27, 28, 31, 32, 35, 36, 39 and/or 40.
  • the expression vector carrying the functional fragment of the transcription factor polynucleotide is a GFAP-AAV vector;
  • the GFAP-AAV vector carries a viral ITR sequence, a CMV enhancer, and a human GFAP promoter , the coding frame of the functional fragment of the transcription factor polynucleotide and the post-transcriptional regulatory element WPRE, etc.;
  • the expression vector can also carry a reporter gene, but the reporter gene is not necessary in practical applications, such as the GFAP-
  • the AAV expression vector can include the following elements in sequence from the 5' to 3' end: viral ITR sequence + enhancer of CMV + promoter of human GFAP + transcription factor polynucleotide and the coding frame of red fluorescent protein mCherry + post-transcriptional regulatory element WPRE +
  • the polynucleotide of the transcription factor is selected from functional polynucleotides encoding NeuroD1, Brn2, Ascl1, Ngn2, Gsx1, Tbr1, Dlx2, Ptf1a, Pax6 and/or Otx2, specifically, selected from SEQ ID NO.: Sequence of 3, 4, 7, 8, 11, 12, 15, 16, 19, 20, 23, 24, 27, 28, 31, 32, 35, 36, 39 and/or 40.
  • the GFAP-AAV expression vector may include the following elements in sequence from the 5' to 3' end: viral ITR sequence + SV40 enhancer + human GFAP promoter + transcription factor polynucleotide + post-transcriptional regulatory element WPRE + viral ITR sequence.
  • the GFAP-AAV expression vector may include the following elements in sequence from the 5' to the 3' end: viral ITR sequence + enhancer of CMV + promoter of human GFAP + VP16 fusion protein + DNA binding region of transcription factor + Post-transcriptional regulatory element WPRE + viral ITR sequence.
  • the GFAP-AAV expression vector may include the following elements in sequence from the 5' to 3' end: viral ITR sequence + CMV enhancer + human truncated GFAP promoter + transcription factor polynucleotide + transcription Post regulatory element WPRE+ viral ITR sequence.
  • the GFAP-AAV expression vector may include the following elements in sequence from the 5' to the 3' end: viral ITR sequence + SV40 enhancer + human truncated GFAP promoter + VP16 fusion protein + transcription factor DNA binding region + post-transcriptional regulatory element WPRE + viral ITR sequence.
  • the GFAP-AAV expression vector may include the following elements in sequence from the 5' to 3' end: viral ITR sequence + SV40 enhancer + human truncated GFAP promoter + transcription factor polynucleotide + transcription Post regulatory element WPRE + viral ITR sequence.
  • the GFAP-AAV expression vector may include the following elements in sequence from the 5' to 3' end: viral ITR sequence + SV40 enhancer + human GFAP promoter + VP16 fusion protein + DNA binding region of transcription factor + Post-transcriptional regulatory element WPRE + viral ITR sequence.
  • the GFAP-AAV expression vector may include the following elements in sequence from the 5' to the 3' end: viral ITR sequence + CMV enhancer + human truncated GFAP promoter + VP16 fusion protein + transcription factor DNA binding region + post-transcriptional regulatory element WPRE + viral ITR sequence.
  • a pharmaceutical composition comprising:
  • the pharmaceutical composition is a liquid preparation or a freeze-dried preparation.
  • the pharmaceutical composition is an injection.
  • the pharmaceutical composition comprises: (A) a combination of functional fragments that promote the expression of transcription factors, or treating glial cells with the combination of functional fragments, so that the glial cells are transdifferentiated and reprogrammed functional neurons or neuron-like;
  • the combination contains Ascl1, or enhanced Ascl1; or Ngn2; or
  • the described combination is selected from the group consisting of:
  • the combination is a combination of enhanced Ascl1 and at least one selected from the group consisting of NeuroD1, Brn2, Ngn2, Gsx1, Tbr1, Dlx2, Ptf1a, Pax6, and Otx2.
  • the combination is a combination of Ascl1 and at least one selected from the group consisting of NeuroD1, Brn2, Ngn2, Gsx1, Tbr1, Dlx2, Ptf1a, Pax6, and Otx2.
  • the combination is a combination of Ngn2 and at least one selected from the group consisting of NeuroD1, Brn2, Ngn2, Gsx1, Tbr1, Dlx2, Ptf1a, Pax6, and Otx2.
  • an artificially reprogrammed neuron or neuron-like wherein the neuron or neuron-like is reprogrammed to have functions by transdifferentiation of glial cells neuron or neuron-like.
  • the artificially reprogrammed neurons or neuron-like cells are prepared by the method described in the second aspect of the present invention.
  • the nervous system disease is nervous system injury or glial cell-derived glioma.
  • Figure 1 shows that the combination of Brn2 and NeuroD1 can induce human glioma cells into neurons.
  • Figures 1A-C show immunofluorescence showing neuronal characteristic markers 14 days after infection of human glioma cells U251 cells with control lentivirus FUGW, single virus FUGW-NeuroD1, and a combination of two viruses, FUGW-Brn2 and FUGW-NeuroD1, respectively Expression of the molecule Tuj1.
  • Figure 1D shows a statistical graph of the ratio of neurons induced by different viruses. "**" represents p ⁇ 0.01. Scale bar: 50 ⁇ m.
  • Figure 2 shows that the combination of Brn2 and NeuroD1 induces the molecular expression properties of neurons.
  • Figure 2A shows that 21 days after glioma cells were infected with lentivirus, the induced neurons expressed the marker molecule MAP2 of mature neurons.
  • Figures 2B-D show that the induced neurons express the marker molecule Synapsin I of mature neurons.
  • Figures 2E-H show the transmitter properties of the induced neurons expressing the glutamatergic neuron marker molecule VGLUT1. Scale bar: 20 ⁇ m.
  • Figure 3 shows that the combination of Brn2 and NeuroD1 induces electrophysiological properties of neurons.
  • Figure 3A shows the cell (with green fluorescence) being recorded by the glass electrode.
  • Figure 3B shows that induced neurons are able to fire action potentials.
  • Figure 3C shows that the postsynaptic current signal of induced neurons was detected, and the postsynaptic current signal disappeared after the addition of blocking agents CNQX and AP5.
  • Figure 4 shows that the combination of Brn2 and NeuroD1 induces neurons to exit the cell cycle.
  • Figure 4A, B show that the Brn2/NeuroD1 combination induces a sharp decrease in the number of cells positive for BrdU when BrdU spacer incorporation is performed at different time periods of virus infection.
  • Figures 4C-F show that the combination of Brn2/NeuroD1 induced a significant decrease in the number of cells positive for BrdU when the label was continuously incorporated with BrdU 5 days after virus infection.
  • Figure 4F arrows indicate that the induced neurons are BrdU negative.
  • "*" represents p ⁇ 0.05.
  • "**" represents p ⁇ 0.01. Scale bar: 50 ⁇ m.
  • Figure 5 shows that the combination of Brn2 and NeuroD1 inhibits the growth of glioma cells.
  • Figures 5A-C show that 14 days after virus infection, immunocytochemical analysis for Ki67 showed a significant reduction in the number of Ki67-positive cells in the Brn2/NeuroD1 combination.
  • Figure 5B arrows indicate that the induced neurons are Ki67 negative.
  • Figure 5D shows the number of cells counted after virus infection at different times. "**" represents p ⁇ 0.01. Scale bar: 50 ⁇ m.
  • Figure 6 shows that AAV viral vectors expressing the reprogramming factors NeuroD1 and Brn2 inhibit glioma growth in animals by inducing transdifferentiated neurons.
  • Figure 6A is the tumor volume at each time point in different administration groups, and
  • Figure 6B is the Real-time PCR analysis results of tumor samples in different administration groups. "*" represents p ⁇ 0.05.
  • Figure 7 shows that adenovirus type 5 vectors expressing the reprogramming factors NeuroD1 and Brn2 inhibit glioma growth in animals by inducing transdifferentiated neurons.
  • Fig. 7A is the tumor volume at each time point in different administration groups
  • Fig. 7B is the HE color development results of tumor samples in different administration groups.
  • "*" represents p ⁇ 0.05.
  • the inventors After extensive and in-depth research, the inventors have unexpectedly discovered a batch of transcription factors or combinations of transcription factors with transdifferentiation and reprogramming functions and a method for transdifferentiation of glial cells into neurons, which can efficiently convert glial cells into neurons in vitro or in vivo. Glial cells transdifferentiate into neurons with electrophysiological functions. Based on such findings, the application scenarios of transcription factors and their combinations were further explored. A combination of some specific transcription factors can synergistically and significantly promote the transdifferentiation of glial cells into neurons.
  • the method of the present invention is applied to the exploration of nerve damage repair or brain glioma drug development, especially in glioma animal models, it is observed that reprogramming causes glioma cells to exit the cell cycle, and the size of the animal's tumor is significantly reduced , the survival time was significantly prolonged. Therefore, this batch of transcription factors or combinations of transcription factors with transdifferentiation and reprogramming functions is expected to be applied in the development of nerve damage repair drugs or glioma drugs.
  • administration refers to the physical introduction of a product of the invention into a subject using any of a variety of methods and delivery systems known to those skilled in the art, including intravenous, intracerebral, intratumoral, intramuscular, subcutaneous , intraperitoneal, spinal or other parenteral routes of administration, such as by injection or infusion.
  • the term “about” may refer to a value or composition within an acceptable error range of a particular value or composition as determined by one of ordinary skill in the art, which will depend in part on how the value or composition is measured or determined. Typically, “about” means ⁇ 10% or ⁇ 20%. For example, about 1:1 means (1 ⁇ 0.2):(1 ⁇ 0.2); or (1 ⁇ 0.1):(1 ⁇ 0.1).
  • reprogramming generally refers to the process of modulating or altering the biological activity of a cell from one biological state to another, usually including differentiation (from progenitor cells) to terminal cells), dedifferentiation (from terminal cells to pluripotent stem cells), transdifferentiation (from one terminal cell to another terminal cell), retrodifferentiation (from terminal cells to progenitor cells), transdifferentiation (from terminal cells to progenitor cells), The process of changing cell fate, such as decision (terminal cells that naturally differentiate from one progenitor cell to another).
  • the "transdifferentiation” or “reprogramming” or “transdifferentiation and reprogramming” refers specifically to the process from one terminal cell to another terminal cell, specifically, the transduction of glial cells A process for functional nerve cells or neuron-like cells.
  • the present invention provides a group of transcription factors with reprogramming function, these transcription factors and their combination have excellent transdifferentiation ability, and can be used to promote the efficiency of transdifferentiation of glial cells into neurons.
  • transcription factor of the invention refers to one or a group of transcription factors necessary for neural cell differentiation selected from the group consisting of NeuroD1, Brn2, Ascl1, Ngn2, Gsx1, Tbr1, Dlx2, Ptf1a, Pax6 and Otx2.
  • the transcription factors of the present invention comprise at least two of the transcription factors.
  • NeuroD1 functional fragment is a polynucleotide or its expressed protein fragment derived from mammals, encoding Neurogenic differentiation 1 transcription factor, NeuroD1 is a bHLH (basic helix-loop-helix) type transcription factor, such as NeuroD1 molecule from human in GenBank Its ID# is 4760, and its protein sequence is shown in SEQ ID NO.: 1; NCBI Reference Sequence: NM_002500.5, and its CDS sequence is shown in SEQ ID NO.: 3.
  • bHLH basic helix-loop-helix
  • Brn2 functional fragment also known as POU3F2, Oct7, N-Oct3 is a polynucleotide or its expressed protein fragment derived from mammals, encoding Pou class 3 homeobox 2 transcription factor
  • Brn2 is a neuron-specific POU-III type transcription factor family , such as the ID# of the Brn2 molecule from people in GenBank is 5454, and its protein sequence is shown in SEQ ID NO.: 5; NCBI Reference Sequence: NM_005604.4, and the CDS sequence is shown in SEQ ID NO.: 7.
  • Ascl1 functional fragment is a polynucleotide or its expressed protein fragment derived from mammals, encoding Achaete-scute homolog 1 transcription factor, Ascl1 is bHLH (basic helix-loop-helix) class transcription factor, such as Ascl1 molecule from human
  • GenBank GenBank is 429, and its protein sequence is shown in SEQ ID NO.: 9; NCBI Reference Sequence: NM_004316.4, and its CDS sequence is shown in SEQ ID NO.: 11.
  • Ngn2 functional fragment also known as Neurog2 is derived from mammalian polynucleotides encoding Neurogenin-2 transcription factor or its expressed protein fragment, Ngn2 is bHLH (basic helix-loop-helix) class transcription factor, such as from human
  • the ID# of the Ngn2 molecule in GenBank is 63973, and its protein sequence is shown in SEQ ID NO.: 13; NCBI Reference Sequence: NM_024019.4, and its CDS sequence is shown in SEQ ID NO.: 15.
  • Gsx1 functional fragment also known as Gsh1 is derived from mammalian polynucleotides encoding GS homeobox 1 transcription factor or its expressed protein fragment.
  • the binding site of Gsx1 in the DNA sequence is 5'-GC[TA][AC] ATTA[GA]-3', such as the ID# of the human Gsx1 molecule in GenBank is 219409, its protein sequence is shown in SEQ ID NO.: 17; NCBI Reference Sequence: NM_145657.3, the CDS sequence is shown in SEQ ID NO. :19.
  • Tbr1 functional fragment is a polynucleotide or its expressed protein fragment derived from mammals, encoding T-box brain transcription factor 1 transcription factor, Tbr1 is a T-box type transcription factor, such as the ID of human Tbr1 molecule in GenBank # is 10716, and its protein sequence is shown in SEQ ID NO.: 21; NCBI Reference Sequence: NM_006593.4, and its CDS sequence is shown in SEQ ID NO.: 23.
  • Dlx2 functional fragment is a polynucleotide or its expressed protein fragment derived from mammals, encoding the distal-less homeobox 2 transcription factor.
  • Dlx2 is a transcription factor involved in the terminal differentiation of interneurons.
  • the Dlx2 molecule from human is in The ID# of GenBank is 1746, and its protein sequence is shown in SEQ ID NO.:25; NCBI Reference Sequence: NM_004405.4, and its CDS sequence is shown in SEQ ID NO.:27
  • the functional fragment of Ptf1a is a polynucleotide or its expressed protein fragment that is derived from mammals and encodes a transcription factor associated with transcription factor 1a.
  • Ptf1a is a transcription factor involved in the development of the pancreas.
  • the ID# of the Ptf1a molecule from human in GenBank is 256297, whose protein sequence is shown in SEQ ID NO.: 29; NCBI Reference Sequence: NM_178161.3, whose CDS sequence is shown in SEQ ID NO.: 31.
  • the functional fragment of Pax6 is a polynucleotide or its expressed protein fragment derived from mammals and encoding a paired box 6 transcription factor.
  • Pax6 is a key transcription factor involved in the development of neural tissues.
  • the ID# of the human Pax6 molecule in GenBank is 5080, its protein sequence is shown in SEQ ID NO.:33; NCBI Reference Sequence:NM_000280.5, CDS sequence is shown in SEQ ID NO.:35.
  • Otx2 functional fragment is a polynucleotide or its expressed protein fragment derived from mammals, encoding orthodenticle homeobox 2 transcription factor, Otx2 belongs to the bicoid homology domain subfamily transcription factor, such as the Otx2 molecule from human in GenBank ID# It is 5015, and its protein sequence is shown in SEQ ID NO.: 37; NCBI Reference Sequence: NM_001270523.2, and its CDS sequence is shown in SEQ ID NO.: 39.
  • any method that can promote the expression of functional fragments of the above-mentioned transcription factors is not particularly limited, including but not limited to direct contact or introduction of inducible factors or functional fragments that promote the expression of transcription factors with the glial cells, Promote the increased expression or activity of any NeuroD1, Brn2, Ascl1, Ngn2, Gsx1, Tbr1, Dlx2, Ptf1a, Pax6, Otx2 transcription factors in glial cells, and promote the glial cells to exhibit functional neural cells or The characteristics of neuronal cells; the inducible factor or the functional fragment that promotes the expression of the transcription factor can be a polynucleotide encoding the transcription factor, or a functional protein or polypeptide after the polynucleotide is translated, or a functional fragment that promotes NeuroD1, Brn2 , Ascl1, Ngn2, Gsx1, Tbr1, Dlx2, Ptf1a, Pax6, Otx2 any transcription factor expressing small molecule drugs, macromolecular
  • the method for promoting the increased expression of functional fragments of the above transcription factors can also be obtained by CRISPR/dCas9 targeting related transcription factor DNA-activated gene expression, or by CRISPR/Cas13 targeting related transcription factor RNA to improve transcription factors. Expression of functional protein was obtained.
  • Those skilled in the art can screen the promotion methods of the above transcription factors according to the existing databases. It should be understood that, based on the functions of the transcription factors disclosed in the present invention on the transdifferentiation of glial cells and their inhibitory effects on nerve damage repair and glioma cells, those skilled in the art can reasonably foresee any substances that have a promoting effect on the above-mentioned transcription factors. All of them have functions on the transdifferentiation of glial cells and the repair of nerve damage and the inhibition of glioma cells.
  • the transcription factor with reprogramming function of the present invention can be used in conjunction with the modified expression element to further improve the expression of the transcription factor of the present invention.
  • glial cells or “glial cells” are used interchangeably and refer to another broad class of cells in neural tissue other than neuronal cells, widely distributed in the central and peripheral nervous systems. In mammals, the ratio of glial cells to neurons is about 10:1. Glial cells in the central nervous system mainly include astrocytes, NG2 glial cells, oligodendrocytes and microglia. Glial cells perform many physiological functions, including biochemical support (such as forming the blood-brain barrier), providing nutrients to neurons, and maintaining extracellular ion balance. In injury or disease states, glial cells become activated and proliferate, and are involved in repair and scarring after brain and spinal cord injury, but cannot differentiate into neuronal cells. The key feature that distinguishes it from neural stem cells is that neural stem cells are self-replicating cells that have not yet been fully differentiated, and have the potential to differentiate into neurons and various glial cells, while glial cells are terminally differentiated cells.
  • the glial cells of the present invention are any human or non-human mammalian astrocytes, NG2 glial cells, oligodendrocytes, microglia, or glial cells in a damaged state, Glial cell-derived tumor cells, etc.; the glial cells in the injured state are the neuronal death and apoptosis caused by mechanical trauma, stroke or neurodegenerative diseases in the tissue or the surrounding environment of the glial cells, resulting in neuronal death.
  • Glial cells in a state where signal transduction is blocked or disordered are generally glioma cells, selected from astrocytomas, oligodendrogliomas, Ependymomas, mixed gliomas, choroid plexus tumors, neuroepithelial tumors of uncertain origin, mixed neuronal and neuroglial tumors, pineal parenchymal tumors, embryonal tumors, neuroblastoma tumors .
  • glioma is abbreviated as "glioma”, also known as “glioma”, and refers to all tumors of neuroepithelial origin in a broad sense and tumors derived from various types of glial cells in a narrow sense. . Glioma is one of the most lethal malignant tumors and the most common primary central nervous system tumor, accounting for 30% of brain and central nervous system tumors, and 80% of brain malignant brain tumors. threat.
  • the glioma cells that can be used in the present invention are not particularly limited, and include various gliomas derived from mammalian central nervous system, such as astrocytoma, oligodendroglioma, ependymoma or neuroblastoma , preferably, derived from astrocytoma or neuroblastoma.
  • the transcription factor with transdifferentiation function and the combination of transcription factors have the ability to induce the transformation of glioma cells into neurons/neurons, and show neuronal cell-specific markers, DCX, Tuj1, Map2, NeuN, Synapsin I.
  • the proliferation of glioblastoma was significantly reduced, the tumor growth slowed down, and the degree of malignancy decreased.
  • the term "delivery system” is not particularly limited, and may be an expression vector containing the polynucleotide sequence encoding the transcription factor into glial cells or glioma cells.
  • a viral vector it can be any viral vector that can utilize the characteristics of viruses to transmit their genomes and bring genetic material into other cells for infection. Can occur in whole in vivo or in cell culture. Including lentivirus vector, adenovirus vector, adeno-associated virus vector, herpes virus vector, poxvirus vector, etc.
  • the delivery system can also be a novel nanoparticle for loading functional fragments of the transcription factor or molecular entities that promote increased expression or activity of the transcription factor, to the periphery of or into the target cell, such as lipids delivery systems such as bulk nanoparticles, metal nanoparticles, and polymer nanoparticles.
  • the delivery system can also be an exosome that is wrapped with a functional fragment of the transcription factor or a molecular entity that promotes the increased expression or activity of the transcription factor, or a functional fragment that is wrapped with the transcription factor or promotes the transcription factor.
  • the delivery system can also be combined with functionally targeted molecules, such as specific monoclonal antibodies and polypeptides targeting glial cells or glioma cells, which can better promote the functional fragments of the transcription factors or promote
  • functionally targeted molecules such as specific monoclonal antibodies and polypeptides targeting glial cells or glioma cells, which can better promote the functional fragments of the transcription factors or promote
  • the targeting of the molecular entity functional fragment with the increased expression or activity of the transcription factor on glial cells or glioma cells increases the efficiency of inducing glial cell transdifferentiation and anti-tumor.
  • the invention also provides a method for inducing transdifferentiation of glial cells or glioma cells into neuron cells or neuron-like cells in vitro and in vivo, thereby achieving the purpose of nerve repair or anti-tumor.
  • inducible factor is any molecular entity that promotes increased expression or activity of a functional fragment of a transcription factor of the invention.
  • a functional fragment containing the transcription factor, a molecular entity promoting the expression or activity enhancement of the transcription factor functional fragment, a molecule containing the transcription factor functional fragment or promoting the expression and activity enhancement of the transcription factor functional fragment can be Entity delivery system, by contacting or administering (for example, injecting) to target cells cultured in vitro, allowing glial cells to passively absorb or reach the interior of glial cells through the delivery system to achieve in vitro differentiation of neurons and inhibit tumor cells proliferation.
  • the cell clusters successfully transdifferentiated in vitro can also be transplanted to achieve nerve repair at the site of nerve injury.
  • a functional fragment containing the transcription factor, a molecular entity promoting the expression or activity enhancement of the transcription factor functional fragment, a molecule containing the transcription factor functional fragment or promoting the expression and activity enhancement of the transcription factor functional fragment can be Entity delivery system, by contacting or administering (eg, injecting) to the site of nerve injury or tumor foci, allowing the passive absorption of glial cells or reaching the interior of glial cells through the delivery system to effect in vitro differentiation of neurons and inhibition of tumors proliferation of cells.
  • a method of direct in vivo induction would facilitate in situ repair of nerve damage and in situ tumor suppression.
  • the molecular targeting specific to glial cells or glioma is installed on the delivery system carrying the functional fragment of the transcription factor or the molecular entity that promotes the expression and activity enhancement of the functional fragment of the transcription factor.
  • the induction of neuronal transdifferentiation can be achieved by ectopic injection.
  • the present invention also provides a pharmaceutical composition that contains any molecular entity that promotes the expression or activity enhancement of the transcription factor functional fragment or contains the transcription factor functional fragment or promotes the expression and activity enhancement of the transcription factor functional fragment.
  • a pharmaceutical composition that contains any molecular entity that promotes the expression or activity enhancement of the transcription factor functional fragment or contains the transcription factor functional fragment or promotes the expression and activity enhancement of the transcription factor functional fragment.
  • the pharmaceutical composition of the present invention usually contains 10 10 -10 13 PFU of AAV virus particles, preferably 10 11 -10 13 PFU of AAV virus particles, more preferably 10 10 -10 12 PFU of AAV virus particles.
  • the pharmaceutical composition of the present invention generally contains lentiviral particles of 10 7 -10 10 PFU, preferably lentiviral particles of 10 7 -10 9 PFU, more preferably lentiviral particles of 10 8 -10 9 PFU.
  • the pharmaceutical composition of the present invention usually contains 10 8 -10 11 PFU adenovirus particles, preferably 10 8 -10 10 PFU adenovirus particles, more preferably 10 9 -10 10 PFU adenovirus particles.
  • the term "pharmaceutically acceptable carrier” refers to a carrier for administration of a therapeutic agent, including various excipients and diluents. They are not essential active ingredients per se and are not unduly toxic after administration. Suitable carriers are well known to those of ordinary skill in the art. Pharmaceutically acceptable carriers in the compositions may contain liquids such as water, saline, buffers. In addition, auxiliary substances such as fillers, lubricants, glidants, wetting or emulsifying agents, pH buffering substances and the like may also be present in these carriers. The carrier may also contain cell transfection reagents.
  • the pharmaceutical composition of the present invention can be obtained after mixing the expression vector and a pharmaceutically acceptable carrier.
  • the mode of administration of the composition of the present invention is not particularly limited, and representative examples include but are not limited to: intravenous injection, subcutaneous injection, brain injection, intrathecal injection, and spinal cord injection.
  • the delivery system of the present invention containing any molecular entity that promotes the expression or activity enhancement of the transcription factor functional fragment or the delivery system that contains the transcription factor functional fragment or the molecular entity that promotes the expression and activity enhancement of the transcription factor functional fragment or
  • the functional nerve groups can be used to prepare drugs for repairing nerve damage or inhibiting the proliferation and deterioration of glioblastoma.
  • the invention innovatively obtains a batch of transcription factors with reprogramming function, and explores the transdifferentiation ability of transcription factors and their combinations, which can potentially be applied to different scenarios: such as nerve damage repair, according to the damage situation, Selective use of medium and high-efficiency transcription factors and combinations of transcription factors; for glioblastoma, transcription factors and combinations of transcription factors with higher transformation efficiency are required to rapidly downregulate the malignant degree of glioblastoma .
  • the expression element of the transcription factor used for gene therapy is further modified, and the efficiency of the transcription factor to promote the transdifferentiation of glial cells into neurons is significantly improved.
  • the combination of transcription factors used in the present invention can transdifferentiate human glioma cells into neurons, and cause glioma cells to exit the cell cycle and no longer proliferate.
  • injection of adeno-associated virus containing the combination of transcription factors can significantly reduce tumor size and prolong animal survival time.
  • the main advantages of the present invention include:
  • glial cells are transformed through passive absorption or delivery systems
  • SEQ ID NO: 1 (hNeuroD1 amino acid sequence)
  • SEQ ID NO: 2 (mNeuroD1 amino acid sequence)
  • SEQ ID NO: 4 (mNeuroD1 nucleotide sequence)
  • SEQ ID NO: 8 (mBrn2 nucleotide sequence)
  • SEQ ID NO: 12 (mAscl1 nucleotide sequence)
  • SEQ ID NO: 14 (mNgn2 amino acid sequence)
  • SEQ ID NO: 16 (mNgn2 nucleotide sequence)
  • SEQ ID NO: 18 (mGsx1 amino acid sequence)
  • SEQ ID NO: 20 (mGsx1 nucleotide sequence)
  • SEQ ID NO: 24 (mTbr1 nucleotide sequence)
  • SEQ ID NO: 26 (mDlx2 amino acid sequence)
  • SEQ ID NO: 28 (mDlx2 nucleotide sequence)
  • SEQ ID NO: 34 (mPax6 amino acid sequence)
  • SEQ ID NO: 36 (mPax6 nucleotide sequence)
  • SEQ ID NO: 40 (mOtx2 nucleotide sequence)
  • SEQ ID NO: 43 (shorthGFP nucleotide sequence)
  • SEQ ID NO: 44 (VP16 amino acid sequence)
  • SEQ ID NO: 45 (VP16 nucleotide sequence)
  • SEQ ID NO: 46 (SV40 nucleotide sequence)
  • the immunochromatization of cultured cells refers to "Direct conversion of fibroblasts to functional neurons by defined factors" (Vierbuchen, T. et al. Nature 463, 1035-1041 (2010)). Immunochromatographic experiments on tissue sections were performed according to published methods.
  • the primary antibodies used in immunochromatography include: mouse anti-NeuN (Millipore, 1:100), rabbit anti-Dsred (Clontech, 1:500), mouse anti-Tuj1 (Covance, 1:500), mouse anti-Map2 (Sigma, 1:500), rabbit anti-GFP (Invitrogen, 1:1,000), chick anti-GFP (Invitrogen, 1:1,000), rabbit anti-Synapsin I (Millipore, 1:1,000), rabbit anti-VGLUT1 ( Synaptic Systems, 1:500), rabbit anti-Ki67 (1:200; RM-9106; Thermo Fisher Scientific), mouse anti-BrdU (1:200; B2531; Sigma).
  • FITC-, Cy3- and Cy5-conjugated secondary antibodies were purchased from Jackson Immunoresearch.
  • the cultured human glioma cells were incubated with 10 mM BrdU (Sigma) for 2 h or continuously cultured according to the experimental requirements, and the color of BrdU was detected by anti-BrdU antibody immunodetection. Proliferating cells were also detected using Ki67 antibody.
  • cell numbers were counted at different time points (days 0, 3 , 7, 14 and 21) in a 24-well plate (5 x 104 cells/well).
  • NG2 cells were plated and cultured for 24 hours before adding lentivirus, and the medium was changed 24 hours after infection: DMEM/F12, B27, Glutamax and penicillin/streptomycin. After 6-7 days of infection, brain-derived neurotrophic factor (BDNF; PeproTech, 20 ng/ml) was added to the medium every three days.
  • BDNF brain-derived neurotrophic factor
  • NG2 cells Most of the cultured mouse NG2 cells were immunopositive for the NG2 glial cell marker NG2, and a small number of cells expressed oligodendrocyte marker molecules O4 and CNPase, but no neuron marker molecule Tuj1 and stem cell marker molecules Sox2 and CNPase were detected. Expression of Oct4.
  • glial cell-specific promoters can achieve similar transdifferentiation functions, but the transformation efficiency is slightly higher.
  • the in vitro models of glial cell transdifferentiation are unified in One vector type and under the same promoter.
  • the GFAP promoter was cloned on the vector template of AAV-FLEX-Arch-GFP (Addgene, #22222) to replace the CAG promoter and retained the CMV enhancer, and then replaced the GFP with the coding frame of mCherry to obtain the AAV-mCherry plasmid (control group) .
  • the transcription factor is cloned into the AAV-mCherry plasmid to obtain the AAV-mNeurog2/mCherry plasmid, and the target gene can specifically target astrocytes under the action of the GFAP promoter.
  • the viral AAV-mCherry or AAV-transcription factor/mCherry was injected into the lateral tectum of adult wild-type mice, and then brain tissue samples were collected at different time points. On days 3 and 30 of virus injection, the control virus AAV-mCherry was observed whether mCherry co-localized with NeuN in mice with virus AAV-transcription factor/mCherry. In order to demonstrate that induced neurons are functionally active neurons, physiological recordings of AAV virus-infected midbrain were performed simultaneously.
  • the inward Na+ current and outward K+ current were recorded in the voltage-clamp mode, the proportion of the recorded action potentials and postsynaptic currents were counted, and the post-synaptic current signal disappeared by the blocker NBQX. And whether the post-synaptic current signal appears after washing out, to judge whether the induced neuron integrates into the neural circuit to establish synaptic connection, so as to judge whether it is a functional neuron.
  • the AAV virus was performed with reference to mouse brain atlas. After virus injection, the dorsal midbrain and spinal cord were collected at different time points for immunochromatization or brain slice recording. The concentration of virus injection in the intact spinal cord and the injured spinal cord, the speed and the injection volume per injection are consistent with the brain region, and the injection in the spinal cord is at an angle of 30°.
  • mice The loss of sensory afferents after thoracic spinal cord injury promotes the weakening of the inhibitory effect of the descending inhibitory system in the brainstem, resulting in an oversensitivity of the tail to external stimuli.
  • the test method refers to Basso Mouse Scale for locomotion detects differences in recovery after spinal cord injury in five common mouse strains. J Neurotrauma, 2006.23(5):p.635-59.
  • mice used for glioma model transplantation were seven-week NOD-scid mice.
  • Human glioma cells induced for 3 days or without induction were digested with 0.25% trypsin, and the supernatant was removed by centrifugation to make the cells concentrated to a density of about 2.5 ⁇ 10 5 cells/ ⁇ l.
  • Each mouse brain striatum was transplanted with 2 ⁇ l, which is a total of 2 ⁇ l. 5 x 105 cells. Histochemistry was performed 3 weeks after transplantation or virus injection was performed one week later, followed by immunohistochemistry.
  • Example 1 Functional fragments of single transcription factors promote the transdifferentiation of glial cells into neurons
  • In vitro transdifferentiation efficiency % (the number of virus-infected cells with positive fluorescence expression in which the neuronal marker Tuj1 is positive and spontaneous postsynaptic current can be detected by electrophysiology/total number of virus-infected cells with positive fluorescence expression) ⁇ 100% , on average each transcription factor tested at least 100 transdifferentiated cells that were positive for Tuj1 and had detectable spontaneous postsynaptic currents.
  • Both human and murine transcription factors have the ability to transdifferentiate glial cells into neurons in vitro.
  • Example 2 Functional fragments of single transcription factors promote transdifferentiation of glial cells in the dorsal midbrain
  • VP16 is the activation domain (SEQ ID NO: 45) of VP16 protein from Herpes simplex virus, we cloned its gene sequence into AAV-transcription factor/mCherry plasmid to obtain AAV-VP16-transcription factor/mCherry plasmid.
  • VP16 can be single or multiple strings.
  • the plasmid will translate the fusion protein VP16-transcription factor, thereby enhancing the activation gene expression function of the transcription factor.
  • AAV-VP16-transcription factor/mCherry induced neurons with significantly higher efficiency and faster induction (see Table 3).
  • the enhancer of SV40 can greatly enhance the activity of the hGFAP promoter, so that the target gene can be expressed efficiently in vivo, thereby improving the induction efficiency of neurons (see Table 3).
  • transcription factor sequence VP16 insert Promoter truncation SV40 Insert wild-type hAscl1 SEQ ID NO: 9 75.8% 77.2% 76.4% Enhanced hAscl1 SEQ ID NO: 41 88.4% 89.2% 88.9%
  • Table 4 shows the average transformation efficiency of other transcription factors after using the above transformation strategy.
  • transcription factor sequence VP16 insert Promoter truncation SV40 Insert hNgn2 SEQ ID NO: 13 73.8% 74.2% 74.4% hNeuroD1 SEQ ID NO: 1 68.3% 69.6% 68.5% hDlx2 SEQ ID NO: 25 25.3% 26.3% 25.4%
  • Example 3 The combination of functional fragments of transcription factors further increases the efficiency of glial cell transdifferentiation
  • transcription factors can be expressed in the same vector at the same time, or expressed in different expression vectors respectively, and the expression ratios described in the following table are the molar concentration ratios of the functional proteins expressed in the actual study.
  • the transcription factors NeuroD1, Brn2, Gsx1, Tbr1, Dlx2, Ptf1a, Pax6, and Otx2 several groups of single transcription factors were unexpectedly obtained with low efficiency, but the combination can synergistically improve the efficiency of transcription factors and express functional proteins. The closer the molar concentration ratio is, the higher the conversion efficiency obtained (see Table 5).
  • the transdifferentiation efficiencies of single use were 42.30% and 8.70%, respectively (Table 1), while the transdifferentiation efficiency of combined use (1:1) was 76.2%, showing a synergistic effect.
  • Gsx1+Tbr1, Dlx2+Ptf1a, Pax6+Otx2 can also synergistically significantly increase transdifferentiation efficiency.
  • Ascl1 and Ngn2 are two key transcription factors, and the combination of any of the above transcription factors or transcription factors can achieve significant enhancement of transcription efficiency; and achieve additive synergy or synergy function (see Table 6 and Table 7).
  • SCI Spinal cord injury
  • the transformation efficiency described in Examples 1-3 is more than 50%.
  • the transcription factor or transcription factor combination has the ability to induce the glial cells at the injury site to acquire electrophysiological characteristics, and can accept the input of external signals .
  • the spinal cord injury detection model we found that the reprogramming of neurons by these transcription factors is of great help to the recovery of sensory and motor functions in mice with spinal cord injury, especially the transcription factors described in Examples 1-3 whose conversion efficiency reaches more than 75% or a combination of transcription factors. Exemplary preferred transcription factors and their combinations are shown in Table 8.
  • the polynucleotide functional fragment is constructed on the lentiviral vector to generate a lentiviral plasmid carrying the polynucleotide functional fragment.
  • a transcription factor fragment derived from human NeuroD1 (SEQ ID NO: 3) was constructed into the lentiviral vector to generate the hNeuroD1-IRES-EGFP lentiviral plasmid.
  • BDNF brain-derived neurotrophic factor
  • other transcription factors were tested and it was found that NeuroD1 and Brn2 (SEQ ID NO:7) together could very efficiently transdifferentiate glioma cells U251 into neurons, and the cells took on the morphology of mature neurons (Fig. 1C). , D) The conversion efficiency was 58.3%.
  • glioma cell U251 infection with lentiviruses hNeuroD1-IRES-EGFP and hBrn2-IRES-EGFP the cells were immunofluorescence showed that the induced neurons expressed mature neuron marker molecules MAP2 (Fig. 2A) and synapsin I (Fig. 2B-D). ), and expressed the glutamatergic neuron marker molecule VGLUT1 ( Figure 2E-H), indicating that the induced neurons were mainly excitatory neurons.
  • Neuronal cells are cells that exit the cell cycle and no longer divide. NeuroD1 and Brn2 can induce glioma cells to become neurons, causing glioma cells to exit the cell cycle.
  • BrdU labeling for 2 hours at different time periods (days 1, 3, and 5) of lentiviral infection, followed by immunocytochemical analysis (Fig. 4A). Compared with the control group, the ratio of BrdU-positive glioma cells expressed by NeuroD1 and Brn2 lentiviruses was drastically reduced (Fig. 4B), suggesting that NeuroD1 and Brn2-mediated neuronal reprogramming caused glioma cells to exit the cell cycle.
  • NeuroD1 and Brn2-induced transdifferentiation inhibits the proliferation of glioma cells
  • Ki67 an endogenous molecular marker of proliferating cells
  • Fig. 5A, B we performed quantitative statistics on the number of cells after virus infection at different times, and found that the growth of glioma cells infected with NeuroD1 and Brn2 lentiviruses reached a plateau on day 7 and no longer increased significantly
  • NeuroD1 and Brn2 can induce malignantly proliferating glioma cells to become terminally differentiated neurons and cause glioma cells to exit the cell cycle and no longer proliferate.
  • transcription factors or combinations of transcription factors with a transformation efficiency of more than 50%, and tested the transdifferentiation ability of these groups of transcription factors in glioma cells and their ability to inhibit the proliferation of glioma cells, and found that the transdifferentiation efficiency was Transcription factors or combinations of transcription factors above 75% had the best inhibitory effect on glial cell-derived tumors.
  • Exemplary preferred transcription factors and combinations thereof are shown in Table 9.
  • Example 6 Combinations of functional fragments of transcription factors inhibit the growth of intracerebral glioma cells by reprogramming in vivo
  • Example 5 On the basis of Example 5, we tried to verify the effect of transcription factors on the mouse xenograft model, still taking the combination of NeuroD1 and Brn2 as an example, the specific implementation is as follows:
  • AAV-FLEX-Arch-GFP a fragment derived from human NeuroD1 (SEQ ID No.: 3) was constructed into this vector, resulting in AAV-hNeuroD1-P2A-GFP.
  • P2A is a self-cleaving polypeptide that enables efficient co-expression of hNeuroD1 and GFP.
  • the CDS (SEQ ID No.: 7) fragment derived from the human Brn2 gene was constructed into this vector to obtain AAV-hBrn2-P2A-GFP.
  • AAV viral vectors of NeuroD1 and Brn2 inhibit the growth of glioma cells in the brain
  • mice injected with NeuroD1 and Brn2-induced reprogramming had significantly longer lifespans.
  • transcription factors or combinations of transcription factors with transdifferentiation efficiency higher than 75% were also observed to have obvious tumor suppressive effects in the glioblastoma tumor model.
  • AAV virus vector expressing NeuroD1 and Brn2 inhibits the growth of human glioma U87 BALB/CA-nu mice ectopic inoculation model tumor cells
  • the tumor inhibition rate was calculated according to the following formula:
  • Tumor inhibition rate% (V model group-V administration group)/V model group ⁇ 100%
  • Fig. 6A Real-time PCR analysis of tumor samples found that cells in the experimental group expressed the early neural marker molecule DCX (Fig. 6B), indicating that the glue in animals Plasma cells were induced to become neuronal cells, resulting in inhibition of tumor growth.
  • type 5 adenoviral vectors expressing NeuroD1 and Brn2 can also inhibit human brain gelatin. Growth of tumor cells in ectopic inoculation model of glioma U87 BALB/CA-nu mice.
  • adeno-associated virus cannot replicate autonomously in vivo
  • adenovirus type 5 specific amplification in tumor cells we realized in vivo transdifferentiation therapy to control glioblastoma. effect on tumor recurrence.
  • Ad5-hNeuroD1-P2A-hBrn2 Ad5-AN
  • Ad5-AN Ad5-AN
  • mice with a tumor size of about 100 mm 3 were randomly divided into groups, and the administration started after grouping.
  • the control group was the PBS group, the Ad5-AN-low group at a dose of 3 ⁇ 10 8 PFU and the Ad5-vector-high group at a dose of 1 ⁇ 10 9 PFU, administered once every two days for 5 consecutive doses.
  • the volume of tumor mass was measured and calculated every 3 days, animals were sacrificed at the later stage, and the tumor mass was weighed for biochemical and molecular detection.
  • exosomes derived from mesenchymal cells or glioblastoma cells were extracted from the supernatant of cell culture by density gradient centrifugation and size exclusion separation, the expression of exosome marker protein CD63 was identified by Western blot, and the expression of exosomes was detected by transmission electron microscopy and dynamic light scattering. Shape characteristics and particle size, and the concentration of exosomes was detected by BCA protein quantification.
  • Ascl1-mRNA (NCBI Reference Sequence: NM_004316.4) or other combination of transcription factors described in the present invention is introduced into exosomes by endogenous expression or exogenous introduction.
  • Exosomes derived from glioblastoma will specifically infect human glioblastoma cell lines U251 and U87, and in the logarithmic growth phase of cells, exosomes can be observed to infect human glioblastoma cells.
  • the efficiency of line U251 and U87 induction into neurons can be changed with the concentration gradient of exosome drug, and the rate of related tumor cell proliferation is also proportional to the efficiency of neuron induction.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
PCT/CN2021/117302 2020-09-08 2021-09-08 用于重编程的功能性片段、组合及其应用 Ceased WO2022052964A1 (zh)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CN202180054720.4A CN116437943A (zh) 2020-09-08 2021-09-08 用于重编程的功能性片段、组合及其应用
EP21866017.3A EP4212624A4 (en) 2020-09-08 2021-09-08 FUNCTIONAL FRAGMENT FOR REPROGRAMMING, ASSEMBLY AND APPLICATION THEREOF
US18/024,504 US20240026379A1 (en) 2020-09-08 2021-09-08 Functional fragment for reprogramming, composition, and application thereof
JP2023515253A JP7680072B2 (ja) 2020-09-08 2021-09-08 リプログラミング用機能性断片、組み合わせ、およびその用途
KR1020237011913A KR20230082024A (ko) 2020-09-08 2021-09-08 재프로그래밍을 위한 기능적 단편, 구성 및 이의 응용

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202010934192.9A CN114231489A (zh) 2020-09-08 2020-09-08 用于重编程的功能性片段、组合及其应用
CN202010934192.9 2020-09-08

Publications (1)

Publication Number Publication Date
WO2022052964A1 true WO2022052964A1 (zh) 2022-03-17

Family

ID=80632100

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2021/117302 Ceased WO2022052964A1 (zh) 2020-09-08 2021-09-08 用于重编程的功能性片段、组合及其应用

Country Status (6)

Country Link
US (1) US20240026379A1 (https=)
EP (1) EP4212624A4 (https=)
JP (1) JP7680072B2 (https=)
KR (1) KR20230082024A (https=)
CN (2) CN114231489A (https=)
WO (1) WO2022052964A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023217160A1 (zh) * 2022-05-10 2023-11-16 纽伦捷生物医药科技（上海）有限公司 重组溶瘤病毒的重编程的功能性片段、组合及其应用
WO2025108407A2 (en) 2023-11-23 2025-05-30 Neuexcell Therapeutics (Suzhou) Co., Ltd. Gene therapy compositions and methods for treating glioma

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010053522A2 (en) * 2008-10-29 2010-05-14 The Regents Of The University Of California Methods for identifying and producing neural stem and progenitor cells and their progeny
WO2010144696A1 (en) * 2009-06-11 2010-12-16 Burnham Institute For Medical Research Directed differentiation of stem cells
WO2011091048A1 (en) * 2010-01-19 2011-07-28 The Board Of Trustees Of The Leland Stanford Junior University Direct conversion of cells to cells of other lineages
CN102753690A (zh) * 2010-02-04 2012-10-24 帷幄生物技术公司 用于治疗神经障碍的非遗传修饰性重编程细胞的组合物和方法
WO2015114059A1 (en) * 2014-01-29 2015-08-06 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Trans-differentiation of differentiated cells
WO2017081033A1 (en) * 2015-11-09 2017-05-18 Universite De Nice Sophia Antipolis Cell differentiation or reprogramming using fezf2 and lmo4
CN107435050A (zh) * 2017-06-20 2017-12-05 向孟清 一种将人或动物体细胞诱导为神经干细胞的方法
EP3418378A1 (en) * 2017-06-22 2018-12-26 HI-STEM gGmbH Im Deutschen Krebsforschungszentrum DKFZ Novel methods for the generation and use of human induced neural border stem cells
CN109385404A (zh) * 2018-10-19 2019-02-26 国典(北京)医药科技有限公司 一种诱导干细胞分化为神经元的方法及神经元与应用
US20200002679A1 (en) * 2018-06-05 2020-01-02 Kcellbio Banking Co., Ltd. Composition for cell regeneration comprising cells hypersecreting growth factors, and at least one of neural stem cells, neurons and gabaergic neurons
US20200018746A1 (en) * 2018-03-14 2020-01-16 The Broad Institute, Inc. Three-Dimensional Human Neural Tissues for CRISPR-Mediated Perturbation of Disease Genes
WO2020041142A1 (en) * 2018-08-23 2020-02-27 Rutgers, The State University Of New Jersey Treating spinal cord injury (sci) and brain injury using gsx1

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014037527A1 (en) * 2012-09-07 2014-03-13 Cambridge Enterprise Limited Maturation of mammalian cells by modulation of protein phosphorylation
US10076574B2 (en) 2013-10-25 2018-09-18 Wayne State University Methods, systems and compositions relating to cell conversion via protein-induced in-vivo cell reprogramming
US20210228741A1 (en) * 2018-04-27 2021-07-29 University Of Washington Methods and compositions to stimulate retinal regeneration

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010053522A2 (en) * 2008-10-29 2010-05-14 The Regents Of The University Of California Methods for identifying and producing neural stem and progenitor cells and their progeny
WO2010144696A1 (en) * 2009-06-11 2010-12-16 Burnham Institute For Medical Research Directed differentiation of stem cells
WO2011091048A1 (en) * 2010-01-19 2011-07-28 The Board Of Trustees Of The Leland Stanford Junior University Direct conversion of cells to cells of other lineages
CN102753690A (zh) * 2010-02-04 2012-10-24 帷幄生物技术公司 用于治疗神经障碍的非遗传修饰性重编程细胞的组合物和方法
WO2015114059A1 (en) * 2014-01-29 2015-08-06 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Trans-differentiation of differentiated cells
WO2017081033A1 (en) * 2015-11-09 2017-05-18 Universite De Nice Sophia Antipolis Cell differentiation or reprogramming using fezf2 and lmo4
CN107435050A (zh) * 2017-06-20 2017-12-05 向孟清 一种将人或动物体细胞诱导为神经干细胞的方法
EP3418378A1 (en) * 2017-06-22 2018-12-26 HI-STEM gGmbH Im Deutschen Krebsforschungszentrum DKFZ Novel methods for the generation and use of human induced neural border stem cells
US20200018746A1 (en) * 2018-03-14 2020-01-16 The Broad Institute, Inc. Three-Dimensional Human Neural Tissues for CRISPR-Mediated Perturbation of Disease Genes
US20200002679A1 (en) * 2018-06-05 2020-01-02 Kcellbio Banking Co., Ltd. Composition for cell regeneration comprising cells hypersecreting growth factors, and at least one of neural stem cells, neurons and gabaergic neurons
WO2020041142A1 (en) * 2018-08-23 2020-02-27 Rutgers, The State University Of New Jersey Treating spinal cord injury (sci) and brain injury using gsx1
CN109385404A (zh) * 2018-10-19 2019-02-26 国典(北京)医药科技有限公司 一种诱导干细胞分化为神经元的方法及神经元与应用

Non-Patent Citations (15)

* Cited by examiner, † Cited by third party
Title
"Basso Mouse Scale for localization detection differences in recovery after final core adjustment in five common mouse strains", J NEUROTRAUMA, vol. 23, no. 5, 2006, pages 635 - 59
"Efficient transfer, integration, and sustained long term expression of the transgene in adult rat brain injected with a lentiviral vector", PROC NATL ACAD SCI U S A, vol. 93, pages 11382 - 11388
"NCBI", Database accession no. NM_ 001270523.2
DATABASE Protein 12 January 2022 (2022-01-12), ANONYMOUS: "POU domain, class 3, transcription factor 2 [Mus musculus]", XP055911286, retrieved from Genbank Database accession no. NP_032925 *
DATABASE Protein 19 March 2022 (2022-03-19), ANONYMOUS: "neurogenic differentiation factor 1 [Mus musculus]", XP055911272, retrieved from Genbank Database accession no. NP_035024 *
DATABASE Protein 22 February 2022 (2022-02-22), ANONYMOUS : "POU domain, class 3, transcription factor 2 [Pan troglodytes]", XP055911279, retrieved from Genbank Database accession no. NP_001289356 *
DATABASE Protein 26 July 2016 (2016-07-26), ANONYMOUS: "achaete-scute complex homolog 1, partial [synthetic construct]", XP055911262, retrieved from Genbank Database accession no. BAG73959 *
DATABASE Protein 6 February 2022 (2022-02-06), ANONYMOUS : "neurogenic differentiation factor 1 [Homo sapiens]", XP055911264, retrieved from Genbank Database accession no. NP_002491 *
DENNIS DANIEL J., WILKINSON GREY, LI SAIQUN, DIXIT RAJIV, ADNANI LATA, BALAKRISHNAN ANJALI, HAN SISU, KOVACH CHRISTOPHER, GRUENIG : "Neurog2 and Ascl1 together regulate a postmitotic derepression circuit to govern laminar fate specification in the murine neocortex", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 114, no. 25, 20 June 2017 (2017-06-20), pages E4934 - E4943, XP055911296, ISSN: 0027-8424, DOI: 10.1073/pnas.1701495114 *
MCDONOUGH AMONTERUBIO AARIZONA J ET AL.: "Calibrated Forceps Model of Spinal Cord Compression Injury", JOVE-JOURNAL OF VISUALIZED EXPERIMENTS, 2015
SAMBROOK ET AL.: "Molecular Cloning: Laboratory Manual", 1989, COLD SPRING HARBOR LABORATORY PRESS
See also references of EP4212624A4
TISCORNIA, G.SINGER, O.VERMA, I. M.: "Production and purification of lentivirus vectors", NAT. PROTOCOL., vol. 1, 2006, pages 241 - 245
VIERBUCHEN, T. ET AL., NATURE, vol. 463, 2010, pages 1035 - 1041
VUE TOU YIA, KIM EUISEOK J., PARRAS CARLOS M., GUILLEMOT FRANCOIS, JOHNSON JANE E.: "Ascl1 controls the number and distribution of astrocytes and oligodendrocytes in the gray matter and white matter of the spinal cord", DEVELOPMENT, vol. 141, no. 19, 1 October 2014 (2014-10-01), GB , pages 3721 - 3731, XP055911290, ISSN: 0950-1991, DOI: 10.1242/dev.105270 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023217160A1 (zh) * 2022-05-10 2023-11-16 纽伦捷生物医药科技（上海）有限公司 重组溶瘤病毒的重编程的功能性片段、组合及其应用
JP2025515209A (ja) * 2022-05-10 2025-05-13 紐倫捷生物医薬科技（上海）有限公司 組換え腫瘍溶解性ウイルスのリプログラミングさせる機能的断片、組み合わせ及びその応用
WO2025108407A2 (en) 2023-11-23 2025-05-30 Neuexcell Therapeutics (Suzhou) Co., Ltd. Gene therapy compositions and methods for treating glioma

Also Published As

Publication number Publication date
JP7680072B2 (ja) 2025-05-20
JP2023540130A (ja) 2023-09-21
KR20230082024A (ko) 2023-06-08
EP4212624A1 (en) 2023-07-19
CN114231489A (zh) 2022-03-25
CN116437943A (zh) 2023-07-14
EP4212624A4 (en) 2024-12-18
US20240026379A1 (en) 2024-01-25

Similar Documents

Publication Publication Date Title
CN109069544B (zh) 脑内生成gaba能神经元
WO2021031810A1 (zh) Ptbp1抑制剂在预防和/或治疗功能性神经元死亡相关的神经系统疾病中的应用
CN112386699A (zh) Ptbp1抑制剂在预防和/或治疗功能性神经元死亡相关的神经系统疾病中的应用
JP7680072B2 (ja) リプログラミング用機能性断片、組み合わせ、およびその用途
KR20230093400A (ko) Ccn5를 유효성분으로 포함하는 망막질환 예방 또는 치료용 약학 조성물
JP7620338B2 (ja) 機能性ニューロンへのグリア細胞の分化転換を誘導するためのＮｅｕｒｏｇ２機能性断片送達システム、宿主細胞及び医薬組成物
CN105535992B (zh) Ascl1在诱导星形胶质细胞转分化为功能性神经元中的应用
IL301749A (en) Neurod1 vector
WO2021032068A1 (zh) Ptbp1抑制剂在预防和/或治疗功能性神经元死亡相关的神经系统疾病中的应用
JP7828619B2 (ja) 運動性神経細胞直接交差分化用因子
US20250281648A1 (en) Use of transdifferentiation of glial cells into neurons in prevention or treatment of diseases associated with neuron loss-of-function or death
Kagiava et al. Gene delivery targeted to oligodendrocytes using a lentiviral vector
Mortazavi et al. The evaluation of nerve growth factor over expression on neural lineage specific genes in human mesenchymal stem cells
EP4524243A1 (en) Reprogrammed functional fragment of recombinant oncolytic virus, combination, and application thereof
CA2975101A1 (en) Compounds, compositions, and methods for using hla-f
HK40097397A (en) Functional fragment for reprogramming, composition, and application thereof
CN119265241A (zh) 一种无相分离转录因子介导启始阶段重编程使细胞年轻化的方法
RU2521225C2 (ru) Способ стимулирования регенерации спинного мозга с помощью генетически модифицированных клеток крови пуповины человека
US20260061077A1 (en) Methods and compositions of treating retinal degenerative diseases
US20250281641A1 (en) Vectors for delivery of human growth hormone gene and multiple therapeutic genes into central nervous system by crossing blood brain barrier
JPWO2022052964A5 (https=)
Modo ASNTR 2018 Abstracts
Autar et al. ASNTR Abstracts 2019
CN119790142A (zh) 非神经元细胞转分化为神经元的方法及应用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21866017

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2023515253

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2021866017

Country of ref document: EP

Effective date: 20230411